Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

y Rat Neurons by a GABA-Independent Pathway in presentation P-192. About Neurochem

Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the United States Food and Drug Administration, European Medicines Agency and Swissmedic. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit our Web Site at: www.neurochem.com.

This news release contains forward-looking statements regarding tramiprosate (ALZHEMED(TM)) as well as regarding continuing and further development efforts. These statements are based on the current analysis and expectations of management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results to differ materially from this current analysis and these expectations. Analysis regarding the results of clinical trials may not provide definitive results regarding safety, tolerability or therapeutic benefits. Even if all the endpoints sought in the clinical trials were met (which is not certain), there is no certainty that regulators would ultimately approve tramiprosate (ALZHEMED(TM)) for sale to the public. Risks and uncertainties may include: failure to demonstrate the safety, tolerability and efficacy of our product, that ac
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:9/22/2014)... Sept. 22, 2014 Paragon 28, ... commercial launch of its foot plating system that supplants ... The GORILLA TM R3CON PLATING SYSTEM greatly enhances ... TM & Mini-Monster TM Screw Systems and ... of 10 interchangeable subsystems, the GORILLA TM R3CON ...
(Date:9/22/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... comprehensive and up-to-date publication available covering the neurotechnology industry. ... markets, competitors, and growth rates in four key segments ... 2018. It forecasts the number of systems to be ...
(Date:9/22/2014)... , Sept. 22, 2014  Elusys Therapeutics, Inc. ... treat infectious disease, today announced it has completed ... of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in ... data from these studies support the safety and ... at the intended therapeutic dose. The conclusion of ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2The Market for Neurotechnology: 2014-2018 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6
... 20 Muscadine grape skin powder, from ... /), provided significant protection against radiation damage in an ... reported in April of 2009 at the 100th Annual ... Denver, Colorado.(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/CL01715 )The ...
... prototype 3D display exceeds performance expectations.LIVONIA, Mich., April 20 ... Heritage Hospital surgeons and their medical support team assembled to ... test the new LifeVision(TM) family of 3D technologies developed by ... event marks the first time in history that ...
Cached Medicine Technology:Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects 2Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses 2Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses 3Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses 4
(Date:9/23/2014)... Village, CA (PRWEB) September 23, 2014 ... Dental Office is now offering complimentary oral sedation with ... 15 percent of Americans suffer from dental anxiety or ... uncomfortable for patients; they can also keep patients from ... anxiety or phobia in Westlake Village and surrounding areas ...
(Date:9/23/2014)... YORK, NY (PRWEB) September 23, 2014 ... best innovators in the pharmaceutical industry with their annual ... bestowed at a gala banquet at Gotham Hall in ... and brand managers representing top talent and brands. ... celebrate its accomplishments,” says Anna Stashower, CEO and Publisher ...
(Date:9/23/2014)... Gurnee, IL (PRWEB) September 23, 2014 ... lighting solutions, has expanded its MedMaster™ M4 product ... The luminaire extends the M4 product line – ... green LED options – providing more flexibility when ... of the MedMaster M4 Series include:, ...
(Date:9/23/2014)... 2014 The U.S. Pharmacopeial Convention (USP) ... Health Organization (WHO) regarding the assignment of Biological Qualifiers ... by the Expert Group of the Programme of International ... to the naming of all biologicals that is consistent ... assessment of these drugs. , Hence, USP supports ...
(Date:9/23/2014)... N.J. (PRWEB) September 23, 2014 ... provider of advanced delivery technologies and development ... products, today announced that it had reached ... privately held biopharmaceutical company, Cingulate Therapeutics (CTx), ... of new prescription pharmaceutical products for the ...
Breaking Medicine News(10 mins):Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 2Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3Health News:USP Comments to WHO Regarding Biologics Qualifier Proposal 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 3
... , TUESDAY, March 22 (HealthDay News) -- The death ... and were in remission two years after treatment was similar ... study shows. Italian researchers collected data on 832 patients ... and found that 20 patients died during the follow-up period. ...
... HealthDay Reporter , TUESDAY, March 22 (HealthDay News) -- ... on the rise in the United States despite research that ... say. Fibrates are often prescribed to people with low ... triglycerides, a harmful form of fat circulating in the blood, ...
... , TUESDAY, March 22 (HealthDay News) -- A low-cost ... of 400 seemingly healthy children and teens in a pilot ... screen all school-aged children for heart conditions that can lead ... Children,s Hospital of Philadelphia said in a hospital news release. ...
... , TUESDAY, March 22 (HealthDay News) -- Depression can worsen ... South Korean researchers used X-rays to assess the severity ... and older. The patients were also evaluated for the severity ... of pain were higher in patients whose X-rays showed greater ...
... and welfare reforms, and their use of ,nudge, theory, hark ... of the nineteenth century, according to studies by a University ... in the Lancet . Dr Kim Price,s article ... his second in the Lancet within a year drawing parallels ...
... researchers find when women explore their feelings about being or ... humorous. Findings from the project entitled ,Look at me! Images ... feelings about images of ageing. These findings are presented in ... April. Ageing is undoubtedly about the body, and pressure ...
Cached Medicine News:Health News:Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate 2Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 2Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 3Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 4Health News:Screening Seems to Catch Dangerous Heart Condition in Kids 2Health News:Depression May Boost Arthritis Pain 2Health News:Report indicates that 'new' welfare reforms hark back to Victorians 2Health News:Look at me! 2Health News:Look at me! 3Health News:Look at me! 4
Ribbon malleable, general purpose retractor....
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
The osteotome shafts are manufactured with stainless steel and are available both straight and curved in 1/4" and 1/2" sizes....
... Pulse CDC Compact Cardiac Digital Camera is a ... open, patient-friendly gantry, and provides full sized fields ... into your clinic you need a flexible system ... Find out how the Pulse reduces the ...
Medicine Products: